Mandrake Bio, a pioneering startup in the field of protein design, has successfully raised Rs 16 crore in a pre-seed funding round led by venture capital firms Activate and Antler. The round also attracted investments from Spectrum Impact and DeVC, along with several notable angel investors. This funding will enable Mandrake Bio to further its innovative work in gene editing, which holds promise for both agricultural and medical advancements.
### Mandrake Bio’s Unique Approach
Founded in March 2025 by Tanay Lohia and Kutubuddin Molla, Mandrake Bio is at the forefront of developing programmable gene editing enzymes. The company distinguishes itself by designing custom enzymes, rather than relying on naturally occurring systems like CRISPR Cas9. This approach involves using generative AI and structural biology to create precise gene editing tools that can be applied to various fields, including agriculture and medicine. The startup aims to expedite the development of improved crop varieties and therapies for genetic diseases, potentially transforming these industries by reducing the time and cost associated with traditional methods.
### Competitive Landscape and Funding Environment
The biotechnology sector in India is witnessing a surge in interest from investors, particularly in startups that leverage AI and cutting-edge technologies. Mandrake Bio’s funding round reflects a growing trend where investors are keen on backing innovative solutions that address global challenges. The participation of prominent investors, such as Vijay Chandru and Paras Chopra, underscores the confidence in Mandrake’s potential to disrupt the gene editing space. Despite the competitive landscape with established players like CRISPR Therapeutics and Editas Medicine, Mandrake Bio’s unique technology positions it well to carve out a niche in the market.
### Implications for India’s Startup Ecosystem
Mandrake Bio’s successful funding round is a positive signal for the Indian startup ecosystem, particularly in the biotech and life sciences sectors. It demonstrates the increasing willingness of investors to fund early-stage companies with promising technologies. This trend could encourage more entrepreneurs to venture into complex fields like biotechnology, knowing there is financial support available for groundbreaking ideas. Furthermore, Mandrake’s focus on local and global applications reflects a broader shift in Indian startups from purely tech-driven solutions to those with tangible impacts on health and agriculture.
With the fresh capital, Mandrake Bio plans to expand its research capabilities and validate its gene editing enzymes in wet lab environments. This next phase of development will be crucial in proving the efficacy and commercial viability of its technology. For investors and industry watchers, the progress of Mandrake Bio could serve as a bellwether for the success of similar biotech startups in India. As the company scales its operations, its ability to secure partnerships and licensing deals with seed companies and therapeutic developers will be key areas to monitor.
